NASDAQ · Biotechnology

NRx Pharmaceuticals, Inc. (NRXP) Stock

$3.66 -2.40% NASDAQ: NRXP Healthcare

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases.

Valuation

MetricValue
Price$3.66
Market Cap$63.27M
P/E Ratio-2.92
P/B Ratio-8.77
P/S Ratio28.27
EPS (TTM)$-1.34
52-Week High$5.05
52-Week Low$1.62
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE107.73%
ROA-206.17%
ROCE129.51%
Gross Margin-1600.00%
Operating Margin-1600.00%
Net Margin-10.70%
Debt/Equity-0.07
Current Ratio0.31

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$1.0M
Operating Profit$-95.0M$-44.0M$-28.0M$-20.0M$-16.0M
Net Profit$-93.0M$-40.0M$-30.0M$-25.0M$-29.0M
EPS$-7.44$-0.60$-3.98$-2.39$-1.34
Op Margin————-1324.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$33.0M$26.0M$7.0M$4.0M$13.0M
Total Liabilities$12.0M$18.0M$19.0M$27.0M$29.0M
Cash$28.0M$20.0M$5.0M$1.0M$8.0M
Borrowings$1.0M$11.0M$9.0M$7.0M$1.0M

Latest News

Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation? Insider Monkey · Jul 15, 2026 NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute GlobeNewswire · Jun 25, 2026 NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System GlobeNewswire · Jun 25, 2026 Sector Update: Healthcare Stocks Advance Late Afternoon MT Newswires · Jun 24, 2026 Sector Update: Healthcare MT Newswires · Jun 24, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-38.0M$-40.0M$-22.0M$-11.0M$-14.0M
Investing Cash Flow$0$0$0$0$-3.0M
Financing Cash Flow$28.0M$0$0$3.0M$0
Net Cash Flow$26.0M$-8.0M$-15.0M$-3.0M$6.0M
Free Cash Flow$-38.0M$-40.0M$-22.0M$-11.0M$-14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.08
EV / EBITDA-2.44
FCF Yield-22.13%
Quick Ratio0.31
Interest Coverage-16.00
Return 1Y42.12%
Return 3Y19.46%
Return 5Y-94.81%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
COEPCoeptis Therapeutics Holdings, Inc. $10.99 -8.57% -4.45 $38.62M 0.00%
CUE $32.57 +1.40% -4.05 $85.59M 0.00%
EQ $2.57 +3.21% -5.28 $91.29M 0.00%
HOWL $0.40 -3.04% -0.33 $19.54M 0.00%
IOBTIO Biotech, Inc. $0.01 -27.59% -0.01 $885690 0.00%

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

NRx Pharmaceuticals, Inc. is led by CEO Jonathan C. Javitt, employs 2 people, headquartered in US, publicly traded since 2017.

NRx Pharmaceuticals, Inc. (NRXP) stock trades at $3.66 with a market capitalization of $63.27M. The stock is valued at a price-to-earnings (P/E) ratio of -2.92, price-to-book of -8.77, price-to-sales of 28.27. Over the past 52 weeks the stock has ranged between $1.62 and $5.05, and currently trades 27.6% below its 52-week high.

On profitability, NRx Pharmaceuticals, Inc. generates a return on equity (ROE) of 107.73% — well above the market average, a sign of a high-quality business, return on capital employed of 129.51%, an operating margin of -1600.00%, a net profit margin of -10.70%.

Official website: www.nrxpharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides